Develops Motixafortide, a peptide, for autologous stem cell mobilization, having completed Phase 3 clinical trials. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 9.2× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 13% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $1.2M a year. A small number, but proof the product has real buyers.
A loss of $1.2M against $1.2M in annual sales. And on top of that, sales fell from the year before.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 5/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 13/100.
On our five-subject report card, BLRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BLRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.